Promising dawn in tumor microenvironment therapy: engineering oral bacteria

Wang, Zifei; Sun, Wansu; Hua, Ruixue; Wang, Yuanyin; Li, Yang; Zhang, Hengguo

doi:10.1038/s41368-024-00282-3

Cited by 51 publications

(3 citation statements)

References 276 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This work not only optimizes the ability of clinicians to develop personalized treatment strategies but also provides more treatment options and the potential to improve survival outcomes for patients with glioma. 49 Our research has been validated through DCA, indicating that this tool may assist in guiding clinical decisions, especially in predicting patient survival rates and developing treatment plans.…”

Section: Discussionmentioning

confidence: 91%

A novel ARHGAP family gene signature for survival prediction in glioma patients

Huang,

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

ARHGAP family genes are often used as glioma oncogenic factors, and their mechanism of action remains unexplained. Our research entailed a thorough examination of the immune microenvironment and enrichment pathways across various glioma subtypes. A distinctive 6‐gene signature was developed employing the CGGA cohort, leading to insights into the disparities in clinical characteristics, mutation patterns, and immune cell infiltration among distinct risk categories. Additionally, a unique nomogram was established, grounded on ARHGAPs, with DCA curves illustrating the model's prospective clinical utility in guiding therapeutic strategies. Emphasizing the role of ARHGAP30, integral to our model, its impact on glioma severity and the credibility of our risk assessment model were substantiated through RT‐qPCR, Western blot analysis, and cellular functional assays. We identified 6 ARHGAP family genes associated with glioma prognosis. Analysis using the Kaplan–Meier method indicated a correlation between elevated risk levels and adverse outcomes in glioma patients. The risk score, linked with tumour staging and IDH mutation status, emerged as an independent factor predicting prognosis. Patients in the high‐risk category exhibited increased immune cell infiltration, enhanced tumour mutational burden, more pronounced expression of immune checkpoint genes, and a better response to ICB therapy. A nomogram, integrating the risk score with the pathological features of glioma patients, was developed. DCA analysis and cellular studies confirmed the model's potential to improve clinical treatment outcomes for patients. A novel ARHGAP family gene signature reveals the prognosis of glioma.

show abstract

Section: Discussionmentioning

confidence: 91%

A novel ARHGAP family gene signature for survival prediction in glioma patients

Huang,

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The TME is the cellular milieu in which neoplastic cells or cancer stem cells reside. These include the blood vessels surrounding tumor cells, immune cells, other nontumor cells, the extracellular matrix, and signaling molecules ( 17 , 18 ). The interactions between these components and tumor cells have a significant impact on tumor progression ( 19 , 20 ).…”

Section: Overview Of the Tmementioning

confidence: 99%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress in medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. The tumor microenvironment (TME) includes cancer cells, fibroblasts linked to cancer (CAFs), immune-inflammatory cells, and the substances these cells secrete, along with non-cellular components in the extracellular matrix (ECM). First, the TME mainly plays a role in inhibiting tumor growth and protecting normal cell survival. As tumors progress, the TME gradually becomes a place to promote tumor cell progression. Immune cells in the TME have attracted much attention as targets for immunotherapy. Immune checkpoint inhibitor (ICI) therapy has the potential to regulate the TME, suppressing factors that facilitate tumor advancement, reactivating immune cells, managing tumor growth, and extending the survival of patients with advanced cancer. This review presents an outline of current studies on the distinct cellular elements within the OC TME, detailing their main functions and possible signaling pathways. Additionally, we examine immunotherapy rechallenge in OC, with a specific emphasis on the biological reasons behind resistance to ICIs.

show abstract

“…Moreover, recent advancements in sequencing technologies and microbiome research have unveiled the complex interplay between intratumoral bacteria and cancer, prompting significant interest in their potential roles in oncogenesis and malignancy progression [51][52][53][54][55]. Emerging evidence indicates that intratumoral bacteria, situated within the tumour microenvironment, contribute to the modulation of carcinogenic processes through diverse mechanisms, including carcinogen production, host inflammation modulation and tumour microenvironment alteration [56][57][58].…”

Section: Introductionmentioning

confidence: 99%

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Lu,

Aihaiti,

Abudukeranmu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Recently, research on the human microbiome, especially concerning the bacteria within the digestive system, has substantially advanced. This exploration has unveiled a complex interplay between microbiota and health, particularly in the context of disease. Evidence suggests that the gut microbiome plays vital roles in digestion, immunity and the synthesis of vitamins and neurotransmitters, highlighting its significance in maintaining overall health. Conversely, disruptions in these microbial communities, termed dysbiosis, have been linked to the pathogenesis of various diseases, including digestive system cancers. These bacteria can influence cancer progression through mechanisms such as DNA damage, modulation of the tumour microenvironment, and effects on the host’s immune response. Changes in the composition and function within the tumours can also impact inflammation, immune response and cancer therapy effectiveness. These findings offer promising avenues for the clinical application of intratumoral bacteria for digestive system cancer treatment, including the potential use of microbial markers for early cancer detection, prognostication and the development of microbiome-targeted therapies to enhance treatment outcomes. This review aims to provide a comprehensive overview of the pivotal roles played by gut microbiome bacteria in the development of digestive system cancers. Additionally, we delve into the specific contributions of intratumoral bacteria to digestive system cancer development, elucidating potential mechanisms and clinical implications. Ultimately, this review underscores the intricate interplay between intratumoral bacteria and digestive system cancers, underscoring the pivotal role of microbiome research in transforming diagnostic, prognostic and therapeutic paradigms for digestive system cancers.

show abstract

Promising dawn in tumor microenvironment therapy: engineering oral bacteria

Cited by 51 publications

References 276 publications

A novel ARHGAP family gene signature for survival prediction in glioma patients

A novel ARHGAP family gene signature for survival prediction in glioma patients

Recent advances in understanding the immune microenvironment in ovarian cancer

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Contact Info

Product

Resources

About